{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:41:28Z","timestamp":1785782488847,"version":"3.56.0"},"reference-count":36,"publisher":"Akademiai Kiado Zrt.","issue":"44","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,11,3]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    A lipidcs\u00f6kkent\u00e9s \u2013 a m\u00f6g\u00f6tte felhalmoz\u00f3dott klinikai\n                    vizsg\u00e1lati bizony\u00edt\u00e9kok \u00e9s az ir\u00e1nyelvekben t\u00fckr\u00f6z\u0151d\u0151 jelent\u0151s prevenci\u00f3s\n                    szerepe ellen\u00e9re \u2013 sem a betegek, sem az orvosok \u00e9rt\u00e9krendj\u00e9ben nem \u00e1ll az \u0151t\n                    megillet\u0151 helyen, nagy t\u00e1vols\u00e1g van a gyakorlat \u00e9s az elvek k\u00f6z\u00f6tt.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    A lipidcs\u00f6kkent\u0151 kezel\u00e9s preszt\u00edzs\u00e9nek emel\u00e9se\n                    \u00e9rdek\u00e9ben az LDL-koleszterin cs\u00f6kkent\u00e9s\u00e9nek potenci\u00e1lis nyeres\u00e9g\u00e9t\n                    \u00f6sszehasonl\u00edtottuk az \u00e1ltal\u00e1nosan jobban elfogadott thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00f3\n                    kezel\u00e9s\u00e9vel.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A gyulai B\u00e9k\u00e9s Megyei K\u00f6zponti K\u00f3rh\u00e1z\n                    P\u00e1ndy K\u00e1lm\u00e1n Tagk\u00f3rh\u00e1z\u00e1ban 2020. \u00e1prilis 1-j\u00e9t\u0151l kezd\u0151d\u0151en egy \u00e9ven \u00e1t akut\n                    coronaria szindr\u00f3ma miatt percutan coronariaintervenci\u00f3n \u00e1tesett 531 beteg\n                    adatait dolgoztuk fel. Szimul\u00e1ci\u00f3s vizsg\u00e1latot v\u00e9gezt\u00fcnk, melynek sor\u00e1n a nagy\n                    klinikai vizsg\u00e1latok alapj\u00e1n megbecs\u00fclt\u00fck az optim\u00e1lis lipidcs\u00f6kkent\u00e9s \u00e9s\n                    thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00e1s egy \u00e9vre vonatkoz\u00f3 cardiovascularis prevenci\u00f3s\n                    hat\u00e1s\u00e1t.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    Az akut coronaria szindr\u00f3ma miatt kezelt\n                    531 \u00f6sszes beteg eset\u00e9ben, ha az LDL-koleszterin a felv\u00e9telkor tal\u00e1lt 3,37\n                    mmol\/l \u00e1tlagos szinten maradt volna, az indexesem\u00e9ny ut\u00e1n egy \u00e9v alatt 59 nagy\n                    cardiovascularis esem\u00e9ny bek\u00f6vetkezt\u00e9vel lehetett volna sz\u00e1molni. Ha az\n                    LDL-koleszterint az Eur\u00f3pai Kardiol\u00f3gusok T\u00e1rsas\u00e1g\u00e1nak lipidaj\u00e1nl\u00e1s\u00e1ban igen\n                    nagy kock\u00e1zat\u00fa c\u00e9l\u00e9rt\u00e9knek megadott 1,4 mmol\/l-re cs\u00f6kkenten\u00e9nk le, akkor az\n                    esem\u00e9nyek sz\u00e1ma 13-mal, a teoretikus, igen alacsonynak min\u0151s\u00edthet\u0151, nem c\u00e9l\u00e9rt\u00e9k\n                    0,5 mmol\/l el\u00e9r\u00e9sekor pedig 16-tal kevesebb lenne. Az LDL-koleszterin-szint\n                    cs\u00f6kkent\u00e9s\u00e9vel teh\u00e1t v\u00e1rhat\u00f3an elker\u00fclhet\u0151 lenne 13, illetve 16 nagy\n                    cardiovascularis esem\u00e9ny. Ha thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00e1sra csak aszpirint\n                    kapn\u00e1nak a betegek, egy \u00e9v alatt 14, aszpirin \u00e9s klopidogr\u00e9l kombin\u00e1ci\u00f3val 17,\n                    aszpirint \u00e9s praszugr\u00e9lt vagy tikagrelort egy\u00fctt adva 20-20 esem\u00e9ny lenne\n                    megel\u0151zhet\u0151.\n                    <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic>\n                    Az LDL-koleszterin-c\u00e9l\u00e9rt\u00e9kek\n                    el\u00e9r\u00e9s\u00e9nek alacsony ar\u00e1nyai alapj\u00e1n a lipidcs\u00f6kkent\u0151 kezel\u00e9s optimaliz\u00e1l\u00e1s\u00e1ban\n                    vil\u00e1gszerte jelent\u0151s tartal\u00e9kok vannak. A kardiol\u00f3giai gyakorlat egyik\n                    legs\u00e9r\u00fcl\u00e9kenyebb betegcsoportj\u00e1ban, az akut coronaria szindr\u00f3m\u00e1n \u00e1tesett\n                    betegekben a vizsg\u00e1lat eredm\u00e9nyei szerint a lipidcs\u00f6kkent\u00e9ssel \u00e9s a\n                    thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00e1ssal hasonl\u00f3 m\u00e9rt\u00e9k\u0171 cs\u00f6kken\u00e9st lehetne el\u00e9rni a nagy\n                    cardiovascularis esem\u00e9nyek sz\u00e1m\u00e1ban.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A\n                    szimul\u00e1ci\u00f3s vizsg\u00e1lat a k\u00e9tf\u00e9le beavatkoz\u00e1s \u00f6sszem\u00e9rhet\u0151 cardiovascularis\n                    haszn\u00e1t igazolja. Mivel az ir\u00e1nyelvekben el\u0151\u00edrt LDL-koleszterin-c\u00e9l\u00e9rt\u00e9kek\n                    el\u00e9r\u00e9si ar\u00e1nya nem megfelel\u0151 \u2013 amiben az orvosok ter\u00e1pi\u00e1s tehetetlens\u00e9ge nagy\n                    szerepet j\u00e1tszik \u2013, rem\u00e9nyeink szerint eredm\u00e9nyeink meggy\u0151zik a koll\u00e9g\u00e1kat\n                    arr\u00f3l, hogy nagyobb figyelmet kell ford\u00edtani az optim\u00e1lisabb lipidcs\u00f6kkent\u00e9sre.\n                    Orv Hetil. 2024; 165(44): 1746\u20131752.\n                  <\/jats:p>","DOI":"10.1556\/650.2024.33126","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:22:24Z","timestamp":1730776944000},"page":"1746-1752","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Optimaliz\u00e1lt lipidcs\u00f6kkent\u00e9ssel \u00e9s thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00f3 kezel\u00e9ssel el\u00e9rhet\u0151 potenci\u00e1lis cardiovascularis nyeres\u00e9g akut coronaria szindr\u00f3m\u00e1n \u00e1tesett betegekben \u2013 szimul\u00e1ci\u00f3s elemz\u00e9s"],"prefix":"10.1556","volume":"165","author":[{"given":"L\u00e1szl\u00f3","family":"M\u00e1rk","sequence":"first","affiliation":[{"name":"B\u00e9k\u00e9s V\u00e1rmegyei K\u00f6zponti K\u00f3rh\u00e1z, P\u00e1ndy K\u00e1lm\u00e1n Tagk\u00f3rh\u00e1z, Kardiol\u00f3giai Oszt\u00e1ly Gyula Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Gutman","sequence":"additional","affiliation":[{"name":"B\u00e9k\u00e9s V\u00e1rmegyei K\u00f6zponti K\u00f3rh\u00e1z, P\u00e1ndy K\u00e1lm\u00e1n Tagk\u00f3rh\u00e1z, Kardiol\u00f3giai Oszt\u00e1ly Gyula Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Vitrai","sequence":"additional","affiliation":[{"name":"Sz\u00e9chenyi Istv\u00e1n Egyetem, Eg\u00e9szs\u00e9g- \u00e9s Sporttudom\u00e1nyi Kar, Prevent\u00edv Eg\u00e9szs\u00e9gtudom\u00e1nyi Tansz\u00e9k Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Braunwald E. The rise of cardiovascular medicine. Eur Heart J. 2012;\n                    33: 838\u2013846.","DOI":"10.1093\/eurheartj\/ehr452"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Banach M. Statin intolerance: time to stop letting it get in the way\n                    of treating patients. Lancet 2022; 400: 791\u2013793.","DOI":"10.1016\/S0140-6736(22)01643-9"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins\n                    cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,\n                    epidemiologic, and clinical studies. A consensus statement from the European\n                    Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38:\n                    2459\u20132472.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Boncz I, Kov\u00e1cs LG. Utilization of the Hungarian national health\n                    insurance claims data for burden of disease studies. [A nemzeti\n                    eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si adatvagyon haszn\u00e1lata betegs\u00e9gteher-elemz\u00e9sekhez\n                    Magyarorsz\u00e1gon.] Orv Hetil. 2021; 162(Suppl 1): 2\u20135.\n                    [Hungarian]","DOI":"10.1556\/650.2021.32151"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Luengo-Fernandez R, Walli-Attaei M, Gray A, et al. Economic burden\n                    of cardiovascular diseases in the European Union: a population-based cost study.\n                    Eur Heart J. 2023; 44: 4752\u20134767.","DOI":"10.1093\/eurheartj\/ehad583"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document\n                    Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid\n                    modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111\u2013188.\n                    Erratum: Eur Heart J. 2020; 41: 4255.","DOI":"10.1093\/eurheartj\/ehz826"},{"key":"R7","unstructured":"The 8th Hungarian Cardiovascular Consensus Conference. Supplementum.\n                    [A VIII. Magyar Kardiovaszkul\u00e1ris Konszenzus Konferencia. K\u00fcl\u00f6nsz\u00e1m.]\n                    Metabolizmus 2021; 19: 1\u20136 8. [Hungarian]"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Reiber I, M\u00e1rk L, Egy\u00fcd F, et al. Efficacy of high-intensity\n                    rosuvastatin or rosuvastatin\/ezetimibe combined lipid-lowering therapy in\n                    Hungarian patients with hypercholesterolemia at very-high cardiovascular risk \u2013\n                    the first results of the 3T-FIGHT STUDY. [Nagy intenzit\u00e1s\u00fa rosuvastatin vagy\n                    rosuvastatin\/ezetimib kombin\u00e1ci\u00f3s lipidcs\u00f6kkent\u0151 ter\u00e1pia hat\u00e9konys\u00e1ga\n                    hypercholesterinaemi\u00e1s, igen nagy kardiovaszkul\u00e1ris rizik\u00f3j\u00fa magyar betegekben \u2013\n                    a 3T-FIGHT vizsg\u00e1lat els\u0151 eredm\u00e9nyei.] Cardiol Hung. 2023; 53: 633\u2013639.\n                    [Hungarian]","DOI":"10.26430\/CHUNGARICA.2023.53.6.633"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Vrabl\u00edk M, \u0160arkanov\u00e1 I, Brecikov\u00e1 K, et al. Low LDL-C goal\n                    attainment in patients at very high cardiovascular risk due to lacking\n                    observance of the guidelines on dyslipidaemias. PLoS ONE 2023; 18:\n                    e0272883.","DOI":"10.1371\/journal.pone.0272883"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Pedersen TR, Park JG, et al; FOURIER Investigators.\n                    Clinical efficacy and safety of achieving very low LDL-cholesterol\n                    concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary\n                    analysis of the FOURIER trial. Lancet 2017; 390: 1962\u20131971.","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"R11","unstructured":"Giugliano RP, Pedersen TR, Keech AC, et al. Clinical efficacy and\n                    safety of achieving very low LDL-C levels with the PCSK9 inhibitor evolocumab in\n                    the FOURIER outcomes trial. European Society of Cardiology 2017. Clinical Trial\n                    Update I. August 28, 2017."},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment\n                    Trialists\u2019 Collaboration. Efficacy and safety of more intensive lowering of LDL\n                    cholesterol: a meta-analysis of data from 170\u00a0000 participants in 26 randomised\n                    trials. Lancet 2010; 376: 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"J\u00e1nosi A, Pach FP, Erd\u0151s G, et al. Management of patients treated\n                    for myocardial infarction in different regions of Hungary and patient survival\n                    for 10 years. [Sz\u00edvinfarktus miatt kezelt betegek ell\u00e1t\u00e1sa Magyarorsz\u00e1g\n                    k\u00fcl\u00f6nb\u00f6z\u0151 r\u00e9gi\u00f3iban \u00e9s a betegek 10 \u00e9ves t\u00fal\u00e9l\u00e9se.] Orv Hetil. 2021; 162:\n                    1438\u20131450. [Hungarian]","DOI":"10.1556\/650.2021.32205"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"J\u00e1nosi A, Ofner P, Andr\u00e9ka P, et al. Clinical and scientific value\n                    of the Hungarian Myocardial Infarction Registry. [A Nemzeti Sz\u00edvinfarktus\n                    Regiszter klinikai \u00e9s tudom\u00e1nyos \u00e9rt\u00e9ke.] Orv Hetil. 2024; 165: 944\u2013949.\n                    [Hungarian]","DOI":"10.1556\/650.2024.33058"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"M\u00e1rk L, Tajtin\u00e9 Fazekas K, Dani Gy, et al. Assessment of lipid\n                    levels and cholesterol lowering treatment in patients with acute coronary\n                    syndrome at the invasive center of Gyula during the COVID period. [A\n                    lipidcs\u00f6kkent\u0151 kezel\u00e9s alakul\u00e1sa a COVID-id\u0151szakban a gyulai invaz\u00edv centrumban\n                    akut koron\u00e1riaszindr\u00f3m\u00e1n \u00e1tesett betegekben.] Cardiol Hung. 2023; 53: 273\u2013279.\n                    [Hungarian]","DOI":"10.26430\/CHUNGARICA.2023.53.3.273"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"M\u00e1rk L, F\u00fcl\u00f6p P, L\u0151rincz H, et al. The evaluation of lipid-lowering\n                    treatment in patients with acute coronary syndrome in a Hungarian invasive\n                    centre in 2015, 2017, and during the COVID-19 pandemic. The comparison of the\n                    achieved LDL-cholesterol values calculated with Friedewald and Martin\u2013Hopkins\n                    Methods. J Clin Med. 2024; 13: 3398.","DOI":"10.3390\/jcm13123398"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Yusuf S. Two decades of progress in preventing vascular disease.\n                    Lancet 2002; 360(9326): 2\u20133.","DOI":"10.1016\/S0140-6736(02)09358-3"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Fonarow GC, Gawlinski A. Rationale and design of the Cardiac\n                    Hospitalization Atherosclerosis Management Program at the University of\n                    California Los Angeles. Am J Cardiol. 2000; 85(3A): 10A\u201317A.","DOI":"10.1016\/S0002-9149(99)00933-9"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Collaborative overview of randomised trials of antiplatelet therapy\n                    \u2013 I. Prevention of death, myocardial infarction, and stroke by prolonged\n                    antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019\n                    Collaboration. BMJ 1994; 308: 81\u2013106. Erratum: BMJ 1994; 308:\n                    1540.","DOI":"10.1136\/bmj.308.6921.81"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and\n                    Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of\n                    clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:\n                    randomised placebo-controlled trial. Lancet 2005; 366:\n                    1607\u20131621.","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Paciaroni M, Ince B, Hu B, et al. Benefits and risks of clopidogrel\n                    vs. aspirin monotherapy after recent ischemic stroke: a systematic review and\n                    meta-analysis. Cardiovasc Ther. 2019; 2019: 1607181.","DOI":"10.1155\/2019\/1607181"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators; Freij\n                    A, Thors\u00e9n M. Ticagrelor versus clopidogrel in patients with acute coronary\n                    syndromes. N Engl J Med. 2009; 361: 1045\u20131057.","DOI":"10.1056\/NEJMoa0904327"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38\n                    Investigators. Prasugrel versus clopidogrel in patients with acute coronary\n                    syndromes. N Engl J Med. 2007; 357: 2001\u20132015.","DOI":"10.1056\/NEJMoa0706482"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"J\u00e1nosi A, Ferenci T, B\u00e1rsony G, et al. Practice of antiplatelet\n                    therapy in acute myocardial infarction. [A thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00f3 kezel\u00e9s\n                    gyakorlata heveny sz\u00edvinfarktusban.] Orv Hetil. 2022; 163: 743\u2013749.\n                    [Hungarian]","DOI":"10.1556\/650.2022.32453"},{"key":"R25","unstructured":"M\u00e1rk L, Z\u00e1molyi K, Pados Gy, et al. Achieving the target lipid\n                    levels in Hungary, 2004. [C\u00e9l\u00e9rt\u00e9kek el\u00e9r\u00e9se lipidcs\u00f6kkent\u0151 kezel\u00e9s sor\u00e1n \u2013\n                    Magyarorsz\u00e1g 2004.] Orv Hetil. 2005; 146: 147\u2013152. [Hungarian]"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Banach M, Surma S, Toth PP; endorsed by the International Lipid\n                    Expert Panel (ILEP). 2023: The year in cardiovascular disease \u2013 the year of new\n                    and prospective lipid lowering therapies. Can we render dyslipidemia a rare\n                    disease by 2024? Arch Med Sci. 2023; 19: 1602\u20131615.","DOI":"10.5114\/aoms\/174743"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Banach M, Burchardt P, Chlebus K, et al. PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH\n                    guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med\n                    Sci. 2021; 17: 1447\u20131547.","DOI":"10.5114\/aoms\/141941"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular\n                    therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J.\n                    2013; 34: 2940\u20132948.","DOI":"10.1093\/eurheartj\/eht295"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Engi Z, Matuz M, So\u00f3s G, et al. Deprescribing: an essential part of\n                    rational pharmacotherapy. [Gy\u00f3gyszerrosta: a racion\u00e1lis gy\u00f3gyszeres ter\u00e1pia\n                    meghat\u00e1roz\u00f3 eleme.] Orv Hetil. 2023; 164: 931\u2013941. [Hungarian]","DOI":"10.1556\/650.2023.32782"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Simonyi G, Ferenci T, Finta E, et al. Five-year persistence of\n                    statins after acute myocardial infarction in statin-na\u00efve patients. [\u00d6t\u00e9ves\n                    sztatinperzisztencia akut myocardialis infarktus ut\u00e1n, kor\u00e1bban sztatint nem\n                    szed\u0151kben.] Orv Hetil. 2024; 165: 171\u2013176. [Hungarian]","DOI":"10.1556\/650.2024.32966"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Brandts J, Bray S, Villa G, et al.; DA VINCI study group. Optimal\n                    implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and\n                    without atherosclerotic cardiovascular disease across Europe: a simulation based\n                    on the DA VINCI study. Lancet Reg Health Eur. 2023; 31: 100665.","DOI":"10.1016\/j.lanepe.2023.100665"},{"key":"R32","unstructured":"SWEDEHEART Annual report, 2023. Issued in 2024. Available:\n                        https:\/\/www.ucr.uu.se\/swedeheart\/dokument-sh\/arsrapporter-sh\n                    [accessed: 29 March 2024]."},{"key":"R33","unstructured":"Z\u00e1molyi K, Reiber I, Kalina \u00c1. Reality of lipidtherapy. Reality 2004\n                    versus 2007. [A lipidter\u00e1pia val\u00f3s\u00e1ga \u2013 Reality 2004 versus 2007.] Metabolizmus\n                    2008; 6(Suppl C): C3\u2013C6. [Hungarian]"},{"key":"R34","unstructured":"M\u00e1rk L, Vitrai J. Reflection to an article published in the Lege\n                    Artis Medicinae. [A \u201eHol az egyens\u00faly a betegek sz\u0171r\u00e9se \u00e9s a m\u00e1r felismert\n                    esetek \u00e9letm\u00f3drendez\u00e9se k\u00f6z\u00f6tt?\u201d c\u00edm\u0171 cikkre reflekt\u00e1lva. 2023; 33(12):\n                    610\u2013614.] LAM 2024; 34: 45\u201347. [Hungarian]"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Navar AM. Fear-based medical misinformation and disease prevention:\n                    from vaccines to statins. JAMA Cardiol. 2019; 4: 723\u2013724.","DOI":"10.1001\/jamacardio.2019.1972"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Ocsovszky Z, Martos T, Otohal J, et al. Relationship between\n                    cardiovascular risk assessment and health behavior in the light of psychosocial\n                    factors. [A cardiovascularis rizik\u00f3becsl\u00e9s \u00e9s az eg\u00e9szs\u00e9gmagatart\u00e1s kapcsolata\n                    pszichoszoci\u00e1lis t\u00e9nyez\u0151k t\u00fckr\u00e9ben.] Orv Hetil. 2023; 164: 119\u2013131.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32685"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/44\/article-p1746.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/44\/article-p1746.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/44\/article-p1746.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:42:56Z","timestamp":1785318176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/44\/article-p1746.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":36,"journal-issue":{"issue":"44"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33126","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]}}}